Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Inhibiting DDX4 for cancer

September 6, 2024 6:17 AM UTC

Inhibiting DDX4, an RNA helicase that post-transcriptionally regulates RNA within cytoplasmic ribonucleoprotein granules and has normal functions in spermatids, could help treat DDX4-expressing cancers by decreasing tumor growth and invasion.  

DDX4 protein expression was increased in breast cancer, colon cancer, lung cancer, fibrosarcoma, and leiomyosarcoma patient tumor samples compared with corresponding tissues from patients without cancer.  ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

University of Turku